Active Research Studies: Lymphoma

Comprehensive Cancer Centers is currently running the following Phase II and Phase III clinical research studies for lymphoma:

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies
Study#: i3152
Contact Us: For information about this clinical study, Email Us.

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies **OPEN TO COHORTS 1- CLL AND SLL AND COHORT 2- MCL. ON HOLD- COHORTS 3-7**
Study#: i3217
Contact Us: For information about this clinical study, Email Us.

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
Study#: i3285
Contact Us: For information about this clinical study, Email Us.

A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor
Study#: i3320
Contact Us: For information about this clinical study, Email Us.

Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib with Different Ramp- Up Periods in Previously Untreated Subjects with CLL
Study#: Independent/Pending
Contact Us: For information about this clinical study, Email Us.

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination with Standard of Care in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) *PT with ≥2L+ needs to request slot before consenting*
Study#: i3340
Contact Us: For information about this clinical study, Email Us.